Detailed Narrative
Q3 FY26 Financial Performance Overview
Ipca Laboratories reported a consolidated business growth of 6.5% in Q3 FY26, reaching ₹2,393 crores, and an 8.44% growth for the first nine months of FY26, totaling ₹7,258 crores. The consolidated EBITDA margin significantly improved by 263 basis points to 22.5% in Q3 FY26 compared to 19.87% in Q3 FY25. Standalone EBITDA margin also saw an improvement of 184 basis points, reaching 26.09% from 24.25% in the prior year's corresponding quarter.
Domestic and Export Formulation Business Highlights
The domestic business delivered a robust 12% growth in Q3 FY26, outperforming the Indian Pharmaceutical Market (IPM) growth of 8.9%. Within the domestic segment, the chronic business grew by 15% and the acute segment by 8.4%. The company's market share remained at 2.08% as per MAT December 2025. Export formulation business demonstrated strong performance with a 17% growth in Q3 FY26 and a 6% growth for the nine-month period, reaching ₹1,477 crores.
API Business and US Market Performance
The API business remained flat at ₹317 crores in Q3 FY26, though it grew by 14% for the nine-month period to ₹1,051 crores. The combined US business (Ipca and Unichem) showed significant growth, increasing by 17% in Q3 FY26 to ₹395 crores and by 15% for 9M FY26 to ₹1,140 crores. This growth was largely attributed to Ipca's portfolio and the Bayshore portfolio integrated into Unichem.
Unichem Integration and Future Outlook
Unichem's overall business grew only about 2% in the current financial year, primarily due to market share loss in high-volume US products. However, its European business is improving, and the company plans to launch 4-5 more Ipca molecules in the US market over the next 2-3 years. Management targets Unichem's top line to grow 8-10% and its EBITDA margin to improve to 15% in 2-3 years, eventually reaching 20% as filings and registrations in Europe materialize.
EBITDA Margin Drivers and Sustainability
The improvement in EBITDA margins was primarily driven by a favorable product mix and the higher growth of higher-margin businesses. The material cost-to-sales ratio for standalone operations improved by approximately 3.64% in Q3 FY26. Management expects a 1.5% plus annual improvement in EBITDA margins if top-line growth remains in the 10-12% range, with a potential for 300 basis points improvement over the next two years under sustained growth.
Strategic Focus Areas and Capital Allocation
Ipca is focusing on several strategic areas including integrated manufacturing, optimizing US and Unichem integration, and building capabilities in biosimilars. The company currently has 5 biosimilar candidates, with technology transfer initiated for two products. Capital expenditure plans are minimal, with only a ₹50 crore solar project for green energy currently underway. The company maintains a strong liquidity position with over ₹250 crores of cash in the bank, even after paying a ₹181 crore EU fine.
European Market Dynamics and Recovery
The European business, particularly in the UK, has been fiercely competitive, leading to products being sold at losses. However, management noted a sharp recovery in prices in the last month, with recoveries as high as 30-40%. This recovery is expected to improve profitability in this segment, which historically has lower margins compared to other European markets like Scandinavia.